Lilly Raises Profit Forecast on Amylin's $1.26B Payment

Source: Reuters, Toni Clarke and Esha Dey (8/9/12)

"Lilly plans to use the cash to advance its 'pipeline of more than 60 potential new medicines,' among other corporate uses."

Reuters, Toni Clarke and Esha Dey

Eli Lilly and Co (LLY.N) raised its 2012 net profit forecast for the second time in as many weeks to reflect an early payment of $1.26 billion from former partner Amylin Pharmaceuticals Inc, which has been acquired by Bristol-Myers Squibb Co (BMY.N).

Diabetes specialist Amylin had ended its decade-long partnership with Lilly in November. The companies were partners in marketing Amylin's diabetes drug Byetta and its longer-acting version, Bydureon. Bristol, which completed its Amylin purchase on Wednesday, has paid $1.7 billion apart from the cash consideration to cover Amylin's debt and its obligations to Eli Lilly.

Lilly plans to use the cash to advance its "pipeline of more than 60 potential new medicines," among other corporate uses. . .View Full Article

Biopharma Shares Efficacy Data at AUA Meeting
Source: Dr. Leland Gershell (05/01/2025)

These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.

New Cell Treatment for Bladder Cancer Shows Promise
Source: Dr. Andres Maldonado (05/01/2025)

This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial
Source: Streetwise Reports (04/29/2025)

Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock.

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
Source: Streetwise Reports (04/28/2025)

UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis (04/28/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.